ArticleJugan geon-gang gwa jilbyeong2025
Korea Disease Control and Prevention Agency Infectious Disease Big Data: Opening, Integration, Outcomes, and Future Directions.
Article in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A framework for population health observatory from a global perspective: proposed preliminary maturity model and key performance indicators.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The recurring emergence of novel infectious diseases highlights the need for evidence-based policies grounded in real-world data. This study aimed to examine the strategies of the Korea Disease Control and Prevention Agency (KDCA) in establishing and opening up infectious disease big data and to analyze their policy implications. Methods: The KDCA developed the Korea Disease Control and Prevention Agency-COVID19-National Health Insurance Service (K-COV-N) cohort by linking coronavirus disease 2019 (COVID-19) cases and vaccination records with the National Health Insurance Service data, providing access to researchers since 2022. In 2024, the Infectious Disease Big Data Platform was launched, releasing standardized and anonymized datasets for 64 notifiable diseases. In addition, the Infectious Disease Statistics Dashboard and open application programming interface via the Public Data Portal have enhanced accessibility for both researchers and the public. Results: These open data resources have enabled diverse studies, including vaccine effectiveness evaluation, risk analysis for vulnerable populations, post-acute sequelae of COVID-19 (long COVID) research, and assessment of healthcare system impacts. Furthermore, they bridged research and policy practices, supporting the transition toward preventive health policies and strengthening infectious disease response capacity. Conclusions: The infectious disease big data initiatives of the KDCA have functioned as a core infrastructure for evidence-informed policy-making. Integrating additional domains, such as chronic diseases, national health surveys, injuries, and genomics, and applying artificial intelligence-enabled deep analytics and prediction will provide a stronger foundation for protecting population health and enhancing national health security.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.